Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Fig. 3

Tumor DNA methylation analysis. A Global DNA methylation beta plots for pre- and on-treatment samples are shown. X-axis (beta value) represents the ratio of methylated alleles to total alleles (methylated plus unmethylated) for each genomic site, and Y-axis represents the prevalence of the genomic sites with the corresponding beta values. Loci are unmethylated (beta values < 0.2). Green boxes highlight patients in whom many hypermethylated genomic loci decreased in methylation on-treatment compared to pre-treatment levels, indicating demethylation. B Average DNA methylation at promoter sites across the genome in pre- and on-treatment samples. **p < 0.005. C Difference between on-treatment and pre-treatment promoter site methylation for each patient, plotted with mean and 95% CI

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us